Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Precision BioSciences Inc | DTIL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.41 | 03:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.41 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 8.25 - 27.018 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 10.41 | USD |
Precision BioSciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 42.31M | 4.06M | - | 48.73M | -61.32M | -15.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Precision BioSciences News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DTIL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.19 | 10.60 | 9.31 | 9.88 | 29,551 | 0.22 | 2.16% |
| 1 Month | 14.20 | 15.97 | 9.1501 | 12.46 | 74,631 | -3.79 | -26.69% |
| 3 Months | 12.06 | 19.4299 | 9.1501 | 12.42 | 225,470 | -1.65 | -13.68% |
| 6 Months | 9.885 | 19.4299 | 9.1501 | 12.26 | 933,693 | 0.525 | 5.31% |
| 1 Year | 24.993 | 27.018 | 8.25 | 14.04 | 909,655 | -14.58 | -58.35% |
| 3 Years | 283.50 | 431.40 | 8.25 | 72.21 | 927,592 | -273.09 | -96.33% |
| 5 Years | 387.60 | 710.106 | 8.25 | 144.50 | 820,839 | -377.19 | -97.31% |
Precision BioSciences Description
| Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food out of which the Therapeutics segment act as a key revenue driver for the firm. |
